Stimulant Medications Brand Name Generic Name Approved Age Adderall amphetamines 3 and older Concerta methylphenidate 6 and older Cylert* pemoline 6 and older Dexedrine dextroamphetamine 3 and older Dextrostat dextroamphetamine 3 and older Ritalin methylphenidate 6 and older

*Because of its potential for serious side effects affecting the liver, Cylert should not ordinarily be considered as first line drug therapy for ADHD.

Antidepressant and Antianxiety Medications Brand Name Generic Name Approved Age Anafranil clomipramine 10 and older (for OCD) BuSpar buspirone 18 and older Effexor venlafaxine 18 and older Luvox (SSRI) fluvoxamine 8 and older (for OCD) Paxil (SSRI) paroxetine 18 and older Prozac (SSRI) fluoxetine 18 and older Serzone (SSRI) nefazodone 18 and older Sinequan doxepin 12 and older Tofranil imipramine 6 and older (for bed-wetting) Wellbutrin bupropion 18 and older Zoloft (SSRI) sertraline 6 and older (for OCD) Antipsychotic Medications Brand Name Generic Name Approved Age Clozaril (atypical) clozapine 18 and older Haldol haloperidol 3 and older Risperdal (atypical) risperidone 18 and older Seroquel (atypical) quetiapine 18 and older (generic only) thioridazine 2 and older Zyprexa (atypical) olanzapine 18 and older Orap pimozide 12 and older (for Tourette's syndrome). Data for age 2 and older indicate similar safety profile. Mood Stabilizing Medications Brand Name Generic Name Approved Age Cibalith-S lithium citrate 12 and older Depakote divalproex sodium 2 and older (for seizures) Eskalith lithium carbonate 12 and older Lithobid lithium carbonate 12 and older Tegretol carbamazepine any age (for seizures)

References

Burns BJ, Costello EJ, Angold A, Tweed D, Stangl D, Farmer EM, Erkanli A. Data Watch: children's mental health service use across service sectors. Health Affairs, 1995; 14(3): 147-59.

Coyle JT. Psychotropic drug use in very young children [editorial]. Journal of the American Medical Association, 2000; 283(8): 1059-60.

Physician's Desk Reference (PDR). Montvale, NJ: Medical Economics Company, 1999.

Shaffer D, Fisher P, Dulcan MK, Davies M, Piacentini J, Schwab-Stone ME, Lahey BB, Bourdon K, Jensen PS, Bird HR, Canino G, Regier DA. The NIMH diagnostic interview schedule for children version 2.3 (DISC 2.3): description, acceptability, prevalence, rates, and performance in the MECA study. Journal of the Academy of Child and Adolescent Psychiatry, 1996; 35(7): 865-77.

Zito JM, Safer DJ, dosReis S, Gardner JF, Botes M, Lynch F. Trends in the prescribing of psychotropic medications to preschoolers. Journal of the American Medical Association, 2000; 283(8): 1025-30.

NIH-04-4702 Reprinted April 2004